Topics
Glioblastoma | Treatment | Immunotherapy | Vaccines
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Vaccines
*Xiong Z, Raphael I, Olin M, Okada
H, Li X, Kohanbash G.
Glioblastoma
vaccines: past, present, and opportunities.
EBioMedicine.
2024 Jan 5;100:104963. doi:
10.1016/j.ebiom.2023.104963. PMID:
38183840. Review. ˍ
Galanis E, Dooley KE, Keith
Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ,
Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson
SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC,
Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic
antigen-expressing oncolytic measles virus derivative in recurrent
glioblastoma: a phase 1 trial.
Nat
Commun. 2024 Jan
12;15(1):493. doi:
10.1038/s41467-023-43076-7. PMID:
38216554. Interventional
study. ˍ
Squalli
Houssaini A, Lamrabet S, Nshizirungu JP, Senhaji N, Sekal M,
Karkouri M, Bennis S.
Glioblastoma
Vaccines as Promising Immune-Therapeutics: Challenges and Current
Status.
Vaccines
(Basel).
2024 Jun 12;12(6):655. doi:
10.3390/vaccines12060655. PMID:
38932383.
Review. ˍ
Dillman RO, Bota DA.
Next-generation
vaccines are showing promise against glioblastoma.
Oncotarget.
2024 Aug 5;15:543-548. doi:
10.18632/oncotarget.28636. PMID:
39102214. Editorial. ˍ
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O,
Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger
C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C,
Hadaschik D, Garbe C, Hauser TK, la Fougère C, Biskup D,
Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT,
Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li
WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins
A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B,
Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A
real-world observation of patients with glioblastoma treated with
a personalized peptide vaccine.
Nat
Commun. 2024 Aug 11;15(1):6870. doi:
10.1038/s41467-024-51315-8. PMID:
39127809. Observational
study. ˍ
Strika Z, Petković K, Likić R.
Effectiveness
and Safety of mRNA Vaccines in the Therapy of Glioblastoma.
J
Pers Med. 2024 Sep 19;14(9):993. doi:
10.3390/jpm14090993. PMID:
39338247. Perspective. ˍ
Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi SH, Zare I,
Naeimzadeh Y, Mansouri A, Tajbakhsh A, Savardashtaki A, Sahebkar
A.
Personalized mRNA vaccines in
glioblastoma therapy: from rational design to clinical trials.
J
Nanobiotechnology. 2024 Oct 4;22(1):601. doi:
10.1186/s12951-024-02882-x. PMID:
39367418. Review. ˍ
Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, Bagley SJ, Fan Y,
Brem S.
The transformative potential
of mRNA vaccines for glioblastoma and human cancer: technological
advances and translation to clinical trials.
Front
Oncol. 2024 Sep 27;14:1454370. doi:
10.3389/fonc.2024.1454370. PMID:
39399167. Review. ˍ
Tabatabai G, Platten M, Preusser M, Weller M, Wick W, van den Bent
M.
Treatment of glioblastoma patients
with personalized vaccines outside clinical trials: Lessons
ignored?
Neuro
Oncol. 2024 Nov 19:noae225. doi:
10.1093/neuonc/noae225. PMID:
39561243. Comment. ˍ
REFERS
TO:
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B,
Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A,
Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J,
Seitz C, Hadaschik D, Garbe C, Hauser TK, la Fougère C,
Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal
DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S,
Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M,
Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM,
Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A
real-world observation of patients with glioblastoma treated with
a personalized peptide vaccine.
Nat
Commun.
2024 Aug 11;15(1):6870. doi:
10.1038/s41467-024-51315-8. PMID:
39127809. Observational
study.
ˍ
Muragaki
Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori
T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S,
Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T,
Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.
A
randomized, placebo-controlled phase III trial of an autologous,
formalin-fixed tumor vaccine for newly diagnosed glioblastoma:
trial protocol.
Jpn
J Clin Oncol.
2025 May 16:hyaf078. doi:
10.1093/jjco/hyaf078. PMID:
40377260. Interventional study protocol˰ ˍ
Elliott WJ, Gurramkonda N, Guda MR, Tsung AJ, Velpula KK.
Survivin Interference and SurVaxM as
an Adjunct Therapy for Glioblastoma Multiforme.
Cells.
2025 May 21;14(10):755. doi:
10.3390/cells14100755. PMID:
40422257. Review. ˍ
Salahlou R, Farajnia S, Alizadeh E, Dastmalchi S.
Recent
developments in peptide vaccines against Glioblastoma, a review
and update.
Mol
Brain. 2025 Jun 13;18(1):50. doi:
10.1186/s13041-025-01221-x. PMID:
40514725. Review. ˍ
Singh DD, Haque S, Singh AK, Yadav DK.
Advancing
vaccine-based immunotherapy in glioblastoma treatment.
Neurooncol
Adv. 2025 Jun 24;7(1):vdaf135. doi:
10.1093/noajnl/vdaf135. PMID:
40756669. Review. ˍ
AI
Overview
Jha R, Spanehl L, Chen JA, Gessler FA, Arnaout O, Valdes PA, Choi
BD, Peruzzi PP, Bernstock JD, Chiocca EA.
Translational
advancements in tumor vaccine therapies for glioblastomas.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv72-iv83. doi:
10.1093/noajnl/vdaf051. PMID:
40933034. Review. ˍ
Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV,
Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS,
Nistor GI, Dillman RO.
Phase 2 trial
of personal dendritic cell vaccines in newly diagnosed
glioblastoma: 3-year follow-up and correlations with survival.
Hum
Vaccin Immunother. 2025 Sep 12;21(1):2556591. doi:
10.1080/21645515.2025.2556591. PMID:
40938661. Interventional study. ˍ
Barati S, Ghoflchi S, Hosseinzadeh P, Pouramini S, Hosseini H,
Jalili-Nik M.
Promising Cancer Vaccine
for Glioblastoma Therapy: A Focus on mRNA Vaccine.
Cancer
Med. 2025 Sep 15;14(18):e71187. doi:
10.1002/cam4.71187. PMID: 40948290. Review. ˍ
Hill CM, Wang AZ, Hsueh B, Ramirez R, Sherpa N, Costa M, Williams
O, Li M, Dunn GP.
Immunologic
specificity in glioblastoma: Antigen discovery and translational
implications.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv41-iv70. doi:
10.1093/noajnl/vdaf028. PMID:
40933038. Review. ˍ
Hu Y, Leng L, Li B, Qiao Q.
The
advantages of NK cell vaccines in solid carcinoma clinical trials:
conducted by various biology strategy and technology.
Front
Med (Lausanne). 2025 Oct 17;12:1656570. doi:
10.3389/fmed.2025.1656570. PMID:
41179878. Review. ˍ
Stathopoulos A, Glorieux P, Rokas EM, Savelkoul HFJ.
Combined
Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary
and Recurrent Glioblastoma (GBM).
Cancers
(Basel). 2025 Nov 26;17(23):3772. doi:
10.3390/cancers17233772. PMID:
41374974. Review. ˍ
Wu AC, Nakamura Y, Kiyotani K.
Advances
in Neoantigen-Based Cancer Vaccines.
Cancers
(Basel). 2025 Dec 31;18(1):144. doi:
10.3390/cancers18010144. PMID:
41514653. Review. ˍ
Esparragosa
Vázquez I, López-Díaz de Cerio A, Inoges S,
Aristu J, Domínguez P, García-Eulate R,
Calvo-Imirizaldu M, Arbizu J, Rodríguez-Ruiz ME, Irimia P,
Alonso MM, Prósper F, Díez-Valle R, Gállego
Pérez-Larraya J.
Feasibility
and Safety of Autologous Dendritic Cell Vaccination Combined with
Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A
Retrospective Single-Center Series.
Vaccines
(Basel).
2026 Feb 12;14(2):172. doi:
10.3390/vaccines14020172. PMID:
41746092. Observational study. ˍ
Chen
HC, Wong ET, Sarangi S, Elinzano H, Kuburich NA, Mani SA, Ali R,
Cielo D, Svokos KA, Sampath P, Malik AN, Lee CK, Doberstein CE,
Lawler SE, Seyhan A, El-Deiry WS, Chen CC.
Tumor
antigen only (TAO) vaccine platforms for glioblastoma
therapeutics: a systematic review of evidence from clinical
trials.
EClinicalMedicine.
2026 Feb 26;93:103774. doi:
10.1016/j.eclinm.2026.103774. PMID:
41783089. ˍ
Kunz
EM, Foster DT, Durrani A, Kioutchoukova IP, Thakkar R, Davidson C,
Foreman M, Lucke-Wold B.
Active
immunization strategies in glioblastoma - clinical outcomes and
effect modifiers for dendritic vaccines and adoptive cell
therapies: a systematic review.
J
Clin Neurosci.
2026 Mar 14;148:111983. doi:
10.1016/j.jocn.2026.111983. PMID:
41833230˰ ˍ
Shallak
M, Shaik AKB, Gatta A, Volpi M, Accolla RS, Forlani G.
New
concepts for glioblastoma vaccine immunotherapy.
Biomed
J.
2026 Mar 28:100974. doi:
10.1016/j.bj.2026.100974. PMID:
41912068. ˍ
Georges
JF, Clay C, Amin S, Goralczyk A, Mossop C, Bilbao CJ, Valeri A,
Ifrach J, Zaher M, Colman L, Kohler L, Schumann EH, Vu M, Burns
BA, Trivedi A, Liu W, Namekar M, Hofferek CJ, Ernste KJ, Bisht N,
Vazquez-Perez J, Oyewole-Said D, Amanya SB, Rodriguez V, Kraushaar
DC, Okoebor D, Bellayr I, Hartenbach J, Halpert MM, Duus EM,
Aguilar LK, Hsu SH, Zhu JJ, Zvavanjanja RC, Bai Y, Kang SW, Jang
HJ, Lee HS, Garg R, Esquenazi Y, Tandon N, Turtz A, Konduri V,
Decker WK.
Phase
I Clinical Study of DOC1021 (dubodencel) for Adjuvant
Immunotherapy of Glioblastoma.
medRxiv
[Preprint].
2026 Apr 2:2026.03.28.26349013. doi:
10.64898/2026.03.28.26349013. PMID:
41959823. Trial
registration ID:
NCT06805305. ˍ
Long
Z, Liu K.
The
15-year bibliometric landscape of glioblastoma vaccines: Emergence
of combinatorial immunotherapy.
Hum
Vaccin Immunother.
2026 Apr 1;22(1):2650847. doi:
10.1080/21645515.2026.2650847. PMID:
41919662. ˍ
Gao
R, Gong Z, He Y, Jiang Y, Duan H, Wang H.
Emerging
frontiers in glioma therapy: the evolving role of glioma vaccines.
Front
Immunol.
2026 May 11;17:1781820. doi:
10.3389/fimmu.2026.1781820. PMID:
42199419. ˍ
Garfinkle
EAR, Perales-Linares R, Gimple RC, Livingstone AJ, Roberts KF,
Butt OH, Goedegebuure SP, McLellan MD, Chang GS, Hundal J, Yan J,
Navarro JB, Paxton SA, Chattopadhyay S, Cooch N, Perales-Puchalt
A, Stavroulaki K, Rochestie S, Peters J, Junker B, Campian JL,
Chheda MG, Chicoine MR, Kim AH, Willie JT, Zipfel GJ, Dowling JL,
Miller CA, Griffith OL, Griffith M, Gillanders WE, Miller KE,
Mardis ER, Sardesai NY, Dunn GP, Johanns TM.
Adjuvant
personalized multivalent neoantigen DNA vaccination for MGMT
unmethylated glioblastoma: a phase 1 trial.
Nat
Cancer.
2026 May 12. doi:
10.1038/s43018-026-01163-w. PMID:
42120910. Trial
registration ID:
NCT04015700. ˍ
Hashii
Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K,
Takahara-Matsubara M, Goto M, Yanagisawa T, Kikuta A, Kawamoto H,
Hashimoto N, Oka Y, Sugiyama H, Hara J.
Phase
1/2 study of a WT1 peptide-dosing emulsion in pediatric patients
with recurrent/refractory diffuse intrinsic pontine glioma,
glioblastoma, or anaplastic astrocytoma.
Eur
J Cancer.
2026 May 19;242:116808. doi:
10.1016/j.ejca.2026.116808. PMID:
42176363. Trial
registration ID:
NCT02750891˰ ˍ
Ozer
BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos
NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T, Pan E, Youssef M,
Fink KL, Mandel JJ, Taylor LP, Colman H, Dunbar EM, Paleologos N,
Burton EC, Wu J, Leeper HE, Gonzalez J, Penas-Prado M, Raizer JJ,
Veglia E, Craig S, Yuan Y, Chambers C, Wall K, Grajkowska E,
Mendoza T, Armstrong TS, Gilbert MR.
Pembrolizumab,
Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma
Post-Chemoradiation: Results from a Multi-institutional, Phase 2,
Randomized, Placebo-Controlled Trial.
medRxiv
[Preprint].
2026 Jun 24:2026.06.22.26354817. doi:
10.64898/2026.06.22.26354817. PMID:
42396282. Trial
registration ID:
NCT03018288. ˍ
Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala
A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A,
Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP,
von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M,
Poschke I, Wick W, Platten M.
IDH1-mutant
vaccine in newly diagnosed astrocytoma: final analysis of the
multicenter, single-arm, open-label, first-in-human phase 1 NOA16
trial.
Nat
Cancer. 2026 Jul 1. doi:
10.1038/s43018-026-01199-y. PMID:
42387024. Trial
registration ID: NCT02454634. ˍ